SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
IRVINE, Calif., July 13, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL). Investors who purchased or otherwise acquired shares between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.
If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the Food and Drug Administration; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news was announced, shares of Ocular declined in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
